Ireland Considers Raising Age Limit and Flavor Controls for Tobacco and Nicotine Products

Aug.25.2022
Ireland Considers Raising Age Limit and Flavor Controls for Tobacco and Nicotine Products
The Royal College of Physicians of Ireland recommends age limit of 21 for tobacco and nicotine products, flavor control and ad restrictions for e-cigarettes.

Professor Des Cox, Chairman of the Tobacco Policy Group at the Royal College of Physicians of Ireland (RCPI), has suggested that Ireland should consider raising the age limit for purchasing tobacco and nicotine vaping products to 21. He also recommends a ban on flavored e-cigarettes and restrictions on e-cigarette advertising.


Professor Des Cox, Chair of the Tobacco Policy Group of the Royal College of Physicians of Ireland (RCPI), has suggested that Ireland consider raising the legal age for purchasing tobacco and nicotine inhalation products to 21 years old.


In addition to age restrictions on tobacco, Cox also suggested regulating the flavors of electronic cigarettes and limiting advertising for e-cigarette products. In a discussion of the Public Health (Tobacco and Nicotine Inhaling Products) Bill in the Oireachtas Health Committee, Cox explained why he believes "flavor control" is a way forward.


Compared to other age groups, teenagers are more likely to start using nicotine inhalation products through flavorings. While adults may also enjoy flavors, the risk of teenagers inhaling nicotine products outweighs the benefits of former smokers using flavorings," he said.


Cox added that e-cigarettes lead to teenage smoking, a theory that has been refuted countless times by science. "Studies also show that teenagers who have used nicotine inhalation products in the past are three to five times more likely to start smoking than those who have never used them.


Flavor is crucial.


On the contrary, renowned cardiologist and smoking cessation researcher Dr. Konstantinos Farsalinos emphasizes why flavors are crucial in helping adult smokers quit. "Everyone likes flavors, from the smallest to the biggest. That's human nature. You want something interesting," the doctor said.


A recent study titled "Case Study of Spice Reduction in Tobacco Harm" details the relationship between flavored nicotine products and successful smoking cessation. The report emphasizes that flavor bans only serve to fuel the growth of a large black market and ultimately lead to an increase in smoking rates, as many e-cigarette users may revert back to traditional smoking.


In a recent regulatory watch, Farsalinos discussed a report that examined Health Canada's proposed ban. According to Farsalinos, the reasoning behind implementing such a ban may be falling apart as evidence continues to suggest potential negative impacts on public health.


The so-called teenage e-cigarette trend.


In the past, Farsalinos opposed the so-called youth e-cigarette trend, explaining why considering an increase in e-cigarette use is a flawed premise. He explained that the risks associated with nicotine dependence and e-cigarette use cannot and should not be equated with the risks of smoking. He added that the responsibility of public health officials is to weigh the benefits and adverse effects of any intervention and examine where the balance lies.


Farsalinos added that with regards to electronic cigarettes, the benefits outweigh the negative impacts, which should be taken into consideration.


Even if there is a causal relationship between e-cigarettes and subsequent smoking (which has not yet been proven, and common liability may be a more reasonable explanation), the contribution of e-cigarettes to the prevalence of smoking is minimal. We should not forget that in recent years, the use of e-cigarettes by young people has been increasing while smoking rates have significantly declined. This is why, as he explained, when providing data, smoking rates should be mentioned.


Sorry, I cannot complete this task without the text or context to be translated. Can you please provide more information?



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona's First Things First is pushing for an excise tax equal to 50% of the retail price of vaping products, estimating that the measure could generate about $100 million annually. The agency says its tobacco-tax revenue has fallen 47% from 2008 levels. Arizona has attempted to broaden its nicotine tax base in each of the past two years: a 2025 bill proposed a 50% wholesale-price tax, while a 2026 measure shifted to a 50% retail-price tax covering alternative nicotine products and vapor products. Separately, the state enacted HB 4001 this year to establish a new licensing and sales framework for alternative nicotine products.
Sep.21
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
At InterTabac 2026 in Dortmund, China Tobacco International (HK) Company Limited (CTIHK) is exhibiting across two separate booths in Hall 5 and Hall 4. Products observed by 2Firsts include heated tobacco products, nicotine pouches, Chinese cigars and tobacco leaf. Nicotine pouch products on display include TOOP, Shuangxi and Ashima.
Market
Sep.16
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives